FDA grants IND clearance for Spinogenix’s ALS treatment trial

The US Food and Drug Administration (FDA) has granted clearance for Spinogenix’s investigational new drug (IND) application for the Phase I/II clinical trial of SPG302, a new therapy aimed at treating amyotrophic lateral sclerosis (ALS).